A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1

Overview

Sponsor-declared trial summary

Key facts

Sponsor

BioNTech SE

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

5 Mar 2021 → ongoing

Decision date (initial)

2024-07-09

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

External identifiers

EU CT number

2024-512671-12-00

EudraCT number

2020-001400-41

ClinicalTrials.gov

NCT04534205

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Pharmacodynamic, Others, Therapy, Safety, Dose response

Safety run-in phase (Part A):
To assess the safety and tolerability profile of BNT113 in combination with pembrolizumab.

Randomized phase (Part B):
To demonstrate superiority of BNT113 in combination with pembrolizumab compared with pembrolizumab monotherapy in terms of
improved overall survival (OS). To evaluate the efficacy of BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy in terms of progression-free survival (PFS) according to RECIST 1.1 assessed by blinded independent central review (BICR).

Secondary objectives 6

1. Safety run-in Phase (Part A): To assess the anti-tumor activity of BNT113 in combination with pembrolizumab according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by BICR and by investigator's assessment respectively.
2. Randomized phase (Part B): To assess the anti-tumor activity of BNT113 in combination with pembrolizumab compared with pembrolizumab monotherapy according to RECIST 1.1 by investigator's assessment.
3. Randomized phase (Part B): To evaluate the efficacy of BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy in terms of progression-free survival (PFS) rate according to RECIST 1.1 assessed by blinded independent central review (BICR).
4. Randomized phase (Part B): To assess the anti-tumor activity of BNT113 in combination with pembrolizumab compared with pembrolizumab monotherapy according to RECIST 1.1 assessed by BICR.
5. Randomized phase (Part B): To assess the safety and tolerability profile of BNT113 in combination with pembrolizumab compared with pembrolizumab monotherapy.
6. Randomized phase (Part B): To evaluate the efficacy of BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy in terms of progression-free survival (PFS) according to RECIST 1.1 by investigator’s assessment.

Conditions and MedDRA coding

Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

Regulatory references

Scientific advice from competent authorities

Food And Drug Administration

EMA paediatric investigation plan (PIP)

EMEA-003023-PIP01-21

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 15

1. Patients must sign the written informed consent form before any screening procedure. Informed consent must be documented before any trial-specific screening procedure is performed.
2. Patients must be aged ≥18 years on the date of signing the informed consent.
3. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the trial.
4. Patients who present with histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies.
5. Patients who have a tumor that expresses PD-L1 [CPS ≥1] as determined by the CE-marked/FDA-approved CDx PD-L1 IHC 22C3 pharmDx performed according to the manufacturer’s instructions for use.
6. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
7. Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting. Systemic therapy which was completed more than 6 months prior to randomization, if given as part of multimodal treatment for locally advanced disease is allowed.
8. Patients who have measurable disease based on RECIST 1.1 as determined by the site and confirmed by BICR. Tumor lesions situated in a previously irradiated area are considered measurable, if progression has been demonstrated in such lesions by RECIST 1.1.
9. Patients have Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
10. Patients have adequate bone marrow function as defined by hematological parameters.
11. Patients have adequate hepatic function.
12. Patients should have adequate kidney function, assessed by the estimated glomerular filtration rate (eGFR) ≥30 mL/min/min/1.73m² using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
13. Patients should be stable with adequate coagulation, as determined by the investigator.
14. All patients must provide a tumor tissue sample (formalin fixed paraffin embedded [FFPE] blocks or both slides and curls) from archival tissue. Alternatively, a fresh biopsy sample could be provided if a biopsy is performed as part of the patient’s standard clinical practice before the first dose of trial treatment.
15. Women of childbearing potential (WOCBP) must not be pregnant. WOCBP, male patients who are sexually active with WOCBP and female partners of male patients should use a highly effective method of contraception up to at least 6 months after receiving the last dose of trial treatment, and should agree not to donate eggs (ova, oocytes) or sperm.

Exclusion criteria 20

1. Patients are pregnant or breastfeeding.
2. Patients present primary tumor site of nasopharynx (any histology).
3. Patients with uncontrolled intercurrent illness, including but not limited to: Ongoing or active infection which requires systemic treatment with antibiotics on the first dose of trial treatment. Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), myocardial infarction within 3 months before screening, unstable angina pectoris, or cardiac arrhythmia. Arterial thrombosis or pulmonary embolism within ≤6 months before the start of trial treatment, if not on a stable dose of anticoagulants or if in the opinion of the investigator contra-indicates trial inclusion. Evidence or history of interstitial lung disease that, in the opinion of the investigator, is a contraindication for treatment with pembrolizumab, or active non-infectious pneumonitis. Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management. Patients with arterial hypertension need to be on stable anti-hypertensive medication for at least 4 weeks prior to trial entry. Known primary immunodeficiencies. Evidence or history of significant autoimmune disease that (a) required treatment with systemic immunosuppressive treatments, (b) was associated with ongoing treatment with corticosteroids, or (c) was associated with a record of significant end-organ dysfunction (even if transient), which in the opinion of the investigator may suggest increased risk for immune-related AEs. Patients with prior allogeneic stem cell or solid organ transplantation. Any other disease, metabolic dysfunction, physical examination finding, and/or laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates the use of an investigational drug or may render the patient at high risk for complications.
4. Patients with a known allergy, hypersensitivity, or intolerance to BNT113 or its excipients, or to pembrolizumab or its excipients.
5. Patients who have had a splenectomy.
6. Patients who have had major surgery (e.g., requiring general anesthesia) within 4 weeks prior to treatment if fully recovered, or have not fully recovered from surgery, or have major surgery planned during the time of trial participation.
7. Patients who have a known history or a positive test at screening of any of the following: 1. Human immunodeficiency virus (HIV) 1 or 2. Inclusion is allowed if HIV 1/2 infection is adequately controlled and stable on a highly effective antiviral regimen. 2. Hepatitis B infection, as defined by the presence of hepatitis B surface antigen (HbsAg) or hepatitis B virus (HBV) DNA positivity. Testing of HBV DNA is mandatory if hepatitis B core antibody is positive. 3. Hepatitis C (unless considered cured).
8. Patients with another primary malignancy that has not been in complete remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, non-invasive basal or non-invasive squamous cell skin cancer, localized prostate cancer, non-invasive superficial bladder cancer or breast ductal carcinoma in situ).
9. Patients with any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
10. Patients who have received or currently receive the following therapy/medication: 1. Chronic systemic immunosuppressive treatment including corticosteroid treatment (prednisone >10 mg daily orally [PO] or intravenously [IV], or equivalent) in the 7 days prior to the first dose of trial treatment. 2. Prior treatment with other immune modulating agents that was (a) within fewer than 4 weeks (28 days) or 5 half-lives of the agent (whichever is longer) prior to the first dose of BNT113, or (b) associated with immune-mediated adverse events (AEs) that have not resolved prior to the first dose of BNT113 or that pose an additional risk of on-trial complications, per investigator's assessment, or (c) associated with toxicity that resulted in discontinuation of the immune-modulating agent and that poses an additional risk of on-trial complications, per investigator's assessment. 3. Prior treatment with live-attenuated vaccines within 4 weeks before the first dose of BNT113. 4. Prior treatment with an investigational drug (including investigational vaccines) within 4 weeks or 5 half-lives of the agent (whichever is longer) before the planned first dose of BNT113. 5. Ongoing treatment with therapeutic PO or IV antibiotics.
11. Prior treatment with anti-cancer immunomodulating agents, such as blockers of programmed death receptor-1 (PD-1), PD-L1, tumor necrosis factor receptor superfamily member 9 (TNRSF9, 4 1BB, CD137), OX 40, therapeutic vaccines, cytokine treatments, or any investigational agent within 4 weeks or 5 half-lives of the agent (whichever is longer) before the first dose of BNT113.
12. Treatment with non-systemic anti-cancer therapy (e.g., radiotherapy or surgery) within 2 weeks prior to randomization.
13. Current evidence of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade >1 toxicity before the start of treatment, except for hair loss and those Grade 2 toxicities listed as permitted in other eligibility criteria. Patients with Grade 2 neuropathy, dry mouth, or any sequelae from previous treatments may be eligible at investigator's discretion if the conditions are stable and adequately managed (e.g., stable medication) and pose no further medical risk to the patient.
14. Current evidence of new or growing brain or spinal metastases during screening. Patients with known brain or spinal metastases may be eligible if they: 1. had radiotherapy or another appropriate therapy for the brain or spinal metastases, 2. have no neurological symptoms (excluding Grade ≤2 neuropathy), 3. have no evidence of clinical or radiological progression within 4 weeks before signing the informed consent, 4. do not require steroid therapy within 7 days before randomization or are undergoing slow steroid tapering, currently at doses ≤10 mg and neurologically stable. 5. spinal bone metastases are allowed, unless imminent fracture or cord compression is anticipated.
15. Patients who have previously been enrolled in this trial (rescreening is allowed once).
16. Patients with substance abuse or known medical, psychological, or social conditions that in the opinion of the investigator may interfere with the patient's participation in the trial or evaluation of the trial results.
17. Patients affiliated with the investigational site (e.g., a close relative of the investigator or dependent person, such as an employee or student of the trial site) or sponsor. For patients meeting this criterion, a prospective exception and eventual contingencies to be put in place may be defined on a case-by-case basis by the local Institutional Review Board.
18. Patients that have disease suitable for local therapy administered with curative intent.
19. Patients that have a life expectancy of less than 3 months and/or have rapidly progressive disease, as assessed by the treating investigator.
20. Patients with high burden of visceral metastatic disease or location in anatomically critical areas (e.g., causing significant biliary or respiratory obstruction), that in the opinion of the investigator may benefit from treatment with chemotherapy.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 3

1. Safety Run-In Phase (Part A): Occurrence of TEAEs assessed according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) including Grade ≥3, serious and fatal treatment-emergent adverse events (TEAEs) by relationship.
2. Randomized phase (Part B): Overall survival (OS) defined as the time from randomization to death from any cause.
3. Randomized phase (Part B): Progression-free survival (PFS) defined as the time from randomization to the first objective tumor progression (per RECIST 1.1 assessed by BICR), or death from any cause, whichever occurs first.

Secondary endpoints 8

1. Safety run-in phase (Part A): ORR defined as the proportion of patients in whom a CR or PR is observed as best overall response. Duration of response (DoR) defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first. Disease control rate (DCR) defined as the proportion of patients in whom a CR or PR or stable disease (SD) is observed as best overall response.
2. Randomized phase (Part B): Overall response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per RECIST 1.1 assessed by BICR) is observed as best overall response.
3. Randomized phase (Part B): Progression-free survival (PFS) defined as the time from randomization to the first objective tumor progression (per RECIST 1.1 by investigator’s assessment), or death from any cause, whichever occurs first.
4. Randomized Phase (Part B): Objective response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per RECIST 1.1 by investigator’s assessment) is observed as best overall response.
5. Randomized Phase (Part B): PFS rate at 6 months defined as the proportion of patients without objective tumor progression (per RECIST 1.1 assessed by BICR) or death from any cause from randomization until 6 months after randomization. PFS rate at 12 months defined as the proportion of patients without objective tumor progression (per RECIST 1.1 assessed by BICR) or death from any cause from randomization until 12 months after randomization.
6. Randomized Phase (Part B): PFS rate at 6 months defined as the proportion of patients without objective tumor progression (per RECIST 1.1 by investigator’s assessment) or death from any cause from randomization until 6 months after randomization. • PFS rate at 12 months defined as the proportion of patients without objective tumor progression (per RECIST 1.1 by investigator’s assessment) or death from any cause from randomization until 12 months after randomization.
7. Randomized Phase (Part B): Duration of Response (DoR) defined as the time from first objective response (CR or PR per RECIST 1.1 assessed by BICR) to first occurrence of objective tumor progression (PD per RECIST 1.1) assessed by BICR), or death from any cause, whichever occurs first.
8. Randomized Phase (Part B): Occurrence of Treatment Emergent Adverse Events (TEAEs) assessed according to CTCAE v5.0 including Grade ≥3, and serious, fatal treatment-emergent adverse events (TEAEs) by relationship. Occurrence of dose reduction, delay, and discontinuation of trial treatments due to TEAEs.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

BioNTech SE

Sponsor organisation

BioNTech SE

Address

An Der Goldgrube 12, Oberstadt Oberstadt

City

Mainz

Postcode

55131

Country

Germany

Scientific contact point

Organisation

BioNTech SE

Contact name

Clinical Trial Information Desk

Public contact point

Organisation

BioNTech SE

Contact name

Clinical Trial Information Desk

Third parties 7

Locations

11 EU/EEA countries · 70 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 155 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

10 submissions — initial application plus substantial / non-substantial modifications